ARCH Venture Partners
Capital Type
Venture Capital
Investment Size
Undisclosed / varies by deal
Geographic Scope
US, Global
Return Model
Dilutive
Stage Focus
Seed, Early-stage, Company creation
Modality Focus
Platform biotech, Therapeutics
Overview
Major science-first venture firm with a strong company-creation model across breakthrough biology.
Portfolio and Signals
Important because ARCH has meaningful infectious-disease talent and can back technically novel platform companies that may later enter AMR applications.
Access and Engagement
Best fit is frontier science with world-class founders and scientific advisers.
Notable AMR Examples / Programs
Vir-linked infectious-disease expertise on team
Stay Updated
Stay connected so that you don't miss the latest AMR insights and updates.
